![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, June 21, 2014 8:32:37 PM
The stakes are rising significantly higher as AMBS will switch from preclinical news driven company to having drugs in clinical trials (Eltoprazine, MANF for Retinitis Pigmentosis, etc) and LymPro which is on the verge of commercialization (via CLIA certification).
Take note: Wall Street will start discounting future Revenue streams and assign a multiple to this valuation. Also, I believe the financial re engineering strategy is going to be huge here (and now expect that the Reverse split with be 8 to 1 ...or lower)..on leveraging the Diagnostic side of the business (to raise $$$$).
We are the 2nd inning of a 9 inning Ball game (and its really going to heat up very quickly here). New 52 weeks highs coming next week (or the week after). Book it!!!
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM